{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T16:43:38Z","timestamp":1792601018082,"version":"4.5.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2022,9,30]],"date-time":"2022-09-30T00:00:00Z","timestamp":1664496000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,9,30]],"date-time":"2022-09-30T00:00:00Z","timestamp":1664496000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1007\/s40261-022-01202-1","type":"journal-article","created":{"date-parts":[[2022,9,30]],"date-time":"2022-09-30T03:30:56Z","timestamp":1664508656000},"page":"965-975","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Safety of Glucagon-Like Peptide-1 Receptor Agonists: A Real-World Study Based on the US FDA Adverse Event Reporting System Database"],"prefix":"10.1007","volume":"42","author":[{"given":"Tingxi","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2600-0343","authenticated-orcid":false,"given":"Yang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanfeng","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kefu","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shangyi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhigang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,30]]},"reference":[{"key":"1202_CR1","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/653789","volume":"2013","author":"AS Matheus","year":"2013","unstructured":"Matheus AS, Tannus LR, Cobas RA, Palma CC, Negrato CA, Gomes MB. Impact of diabetes on cardiovascular disease: an update. Int J Hypertens. 2013;2013: 653789. https:\/\/doi.org\/10.1155\/2013\/653789.","journal-title":"Int J Hypertens"},{"issue":"1","key":"1202_CR2","doi-asserted-by":"publisher","first-page":"140","DOI":"10.2337\/dc14-2441","volume":"38","author":"SE Inzucchi","year":"2015","unstructured":"Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38(1):140\u20139. https:\/\/doi.org\/10.2337\/dc14-2441.","journal-title":"Diabetes Care"},{"issue":"10","key":"1202_CR3","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1001\/jamacardio.2020.1966","volume":"5","author":"MC Honigberg","year":"2020","unstructured":"Honigberg MC, Chang LS, McGuire DK, Plutzky J, Aroda VR, Vaduganathan M. Use of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes and cardiovascular disease: a review. JAMA Cardiol. 2020;5(10):1182\u201390. https:\/\/doi.org\/10.1001\/jamacardio.2020.1966.","journal-title":"JAMA Cardiol."},{"issue":"13","key":"1202_CR4","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","volume":"377","author":"RR Holman","year":"2017","unstructured":"Holman RR, Bethel MA, Mentz RJ, Thompson VP, Lokhnygina Y, Buse JB, et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2017;377(13):1228\u201339. https:\/\/doi.org\/10.1056\/NEJMoa1612917.","journal-title":"N Engl J Med"},{"issue":"23","key":"1202_CR5","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","volume":"373","author":"MA Pfeffer","year":"2015","unstructured":"Pfeffer MA, Claggett B, Diaz R, Dickstein K, Gerstein HC, K\u00f8ber LV, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015;373(23):2247\u201357. https:\/\/doi.org\/10.1056\/NEJMoa1509225.","journal-title":"N Engl J Med"},{"issue":"8","key":"1202_CR6","doi-asserted-by":"publisher","first-page":"2050","DOI":"10.7150\/ijbs.59965","volume":"17","author":"X Ma","year":"2021","unstructured":"Ma X, Liu Z, Ilyas I, Little PJ, Kamato D, Sahebka A, et al. GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential. Int J Biol Sci. 2021;17(8):2050\u201368. https:\/\/doi.org\/10.7150\/ijbs.59965.","journal-title":"Int J Biol Sci"},{"issue":"2","key":"1202_CR7","doi-asserted-by":"publisher","first-page":"303","DOI":"10.2174\/1381612826666200909142126","volume":"49","author":"K Fujioka","year":"2020","unstructured":"Fujioka K, Harris SR. Barriers and solutions for prescribing obesity pharmacotherapy. Endocrinol Metab Clin North Am. 2020;49(2):303\u201314. https:\/\/doi.org\/10.2174\/1381612826666200909142126.","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"10","key":"1202_CR8","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/j.ecl.2020.02.007","volume":"30","author":"C Liu","year":"2020","unstructured":"Liu C, Zou Y, Qian H. GLP-1R agonists for the treatment of obesity: a patent review (2015-present). Expert Opin Ther Pat. 2020;30(10):781\u201394. https:\/\/doi.org\/10.1016\/j.ecl.2020.02.007.","journal-title":"Expert Opin Ther Pat"},{"key":"1202_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2021.111789","volume":"140","author":"J Aaseth","year":"2021","unstructured":"Aaseth J, Ellefsen S, Alehagen U, Sundf\u00f8r TM, Alexander J. Diets and drugs for weight loss and health in obesity-An update. Biomed Pharmacother. 2021;140: 111789. https:\/\/doi.org\/10.1016\/j.biopha.2021.111789.","journal-title":"Biomed Pharmacother"},{"issue":"11","key":"1202_CR10","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1111\/j.1464-5491.2012.03652.x","volume":"29","author":"M Wenten","year":"2012","unstructured":"Wenten M, Gaebler JA, Hussein M, Pelletier EM, Smith DB, Girase P, et al. Relative risk of acute pancreatitis in initiators of exenatide twice daily compared with other anti-diabetic medication: a follow-up study. Diabet Med. 2012;29(11):1412\u20138. https:\/\/doi.org\/10.1111\/j.1464-5491.2012.03652.x.","journal-title":"Diabet Med"},{"issue":"19","key":"1202_CR11","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Bain SC, Consoli A, Eliaschewitz FG, J\u00f3dar E, Leiter LA, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834\u201344. https:\/\/doi.org\/10.1056\/NEJMoa1607141.","journal-title":"N Engl J Med"},{"issue":"1","key":"1202_CR12","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1053\/j.gastro.2011.02.018","volume":"141","author":"M Elashoff","year":"2011","unstructured":"Elashoff M, Matveyenko AV, Gier B, Elashoff R, Butler PC. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology. 2011;141(1):150\u20136. https:\/\/doi.org\/10.1053\/j.gastro.2011.02.018.","journal-title":"Gastroenterology"},{"issue":"9","key":"1202_CR13","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1056\/NEJMoa1616011","volume":"377","author":"JFE Mann","year":"2017","unstructured":"Mann JFE, \u00d8rsted DD, Brown-Frandsen K, Marso SP, Poulter NR, Rasmussen S, et al. Liraglutide and renal outcomes in type 2 diabetes. N Engl J Med. 2017;377(9):839\u201348. https:\/\/doi.org\/10.1056\/NEJMoa1616011.","journal-title":"N Engl J Med"},{"issue":"9","key":"1202_CR14","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1111\/dom.12926","volume":"19","author":"M Monami","year":"2017","unstructured":"Monami M, Nreu B, Scatena A, Cresci B, Andreozzi F, Sesti G, et al. Safety issues with glucagon-like peptide-1 receptor agonists (pancreatitis, pancreatic cancer and cholelithiasis): Data from randomized controlled trials. Diabetes Obes Metab. 2017;19(9):1233\u201341. https:\/\/doi.org\/10.1111\/dom.12926.","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"1202_CR15","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1603827.","journal-title":"N Engl J Med"},{"issue":"5","key":"1202_CR16","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1111\/jcpt.13472","volume":"46","author":"X Liao","year":"2021","unstructured":"Liao X, Liu Z, Song H. Thyroid dysfunction related to vascular endothelial growth factor receptor tyrosine kinase inhibitors: a real-world study based on FAERS. J Clin Pharm Ther. 2021;46(5):1418\u201325. https:\/\/doi.org\/10.1111\/jcpt.13472.","journal-title":"J Clin Pharm Ther"},{"key":"1202_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.772768","volume":"12","author":"R Yang","year":"2021","unstructured":"Yang R, Yin N, Zhao Y, Li D, Zhang X, Li X, et al. Adverse events during pregnancy associated with entecavir and adefovir: new insights from a real-world analysis of cases reported to FDA adverse event reporting system. Front Pharmacol. 2021;12: 772768. https:\/\/doi.org\/10.3389\/fphar.2021.772768.","journal-title":"Front Pharmacol"},{"issue":"3","key":"1202_CR18","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s40261-021-01006-9","volume":"41","author":"Y Katsuhara","year":"2021","unstructured":"Katsuhara Y, Ikeda S. Correlations between SGLT-2 inhibitors and acute renal failure by signal detection using FAERS: stratified analysis for reporting country and concomitant drugs. Clin Drug Investig. 2021;41(3):235\u201343. https:\/\/doi.org\/10.1007\/s40261-021-01006-9.","journal-title":"Clin Drug Investig"},{"key":"1202_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.616505","volume":"12","author":"C Chen","year":"2021","unstructured":"Chen C, Chen T, Liang J, Guo X, Xu J, Zheng Y, et al. Cardiotoxicity induced by immune checkpoint inhibitors: a pharmacovigilance study from 2014 to 2019 based on FAERS. Front Pharmacol. 2021;12: 616505. https:\/\/doi.org\/10.3389\/fphar.2021.616505.","journal-title":"Front Pharmacol"},{"key":"1202_CR20","unstructured":"Eurpean Medicines Agency. Important medical event list. Available at: https:\/\/www.ema.europa.eu\/en\/human-regulatory\/research-development\/pharmacovigilance\/eudravigilance\/eudravigilance-system-overview. Accessed Jan 2022."},{"key":"1202_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.766125","volume":"12","author":"X Zhou","year":"2021","unstructured":"Zhou X, Ye X, Guo X, Liu D, Xu J, Hu F, et al. Safety of SGLT2 inhibitors: a pharmacovigilance study from 2013 to 2021 based on FAERS. Front Pharmacol. 2021;12: 766125. https:\/\/doi.org\/10.3389\/fphar.2021.766125.","journal-title":"Front Pharmacol"},{"issue":"8","key":"1202_CR22","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1007\/s40264-021-01082-y","volume":"44","author":"J Setyawan","year":"2021","unstructured":"Setyawan J, Azimi N, Strand V, Yarur A, Fridman M. Reporting of thromboembolic events with JAK inhibitors: analysis of the FAERS database 2010\u20132019. Drug Saf. 2021;44(8):889\u201397. https:\/\/doi.org\/10.1007\/s40264-021-01082-y.","journal-title":"Drug Saf"},{"issue":"1","key":"1202_CR23","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/pds.668","volume":"11","author":"EP van Puijenbroek","year":"2002","unstructured":"van Puijenbroek EP, Bate A, Leufkens HG, Lindquist M, Orre R, Egberts AC. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf. 2002;11(1):3\u201310. https:\/\/doi.org\/10.1002\/pds.668.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"2","key":"1202_CR24","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1111\/liv.13308","volume":"37","author":"ES Bj\u00f6rnsson","year":"2017","unstructured":"Bj\u00f6rnsson ES. Hepatotoxicity of statins and other lipid-lowering agents. Liver Int. 2017;37(2):173\u20138. https:\/\/doi.org\/10.1111\/liv.13308.","journal-title":"Liver Int"},{"issue":"4","key":"1202_CR25","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/s41571-021-00597-8","volume":"19","author":"Y Jing","year":"2022","unstructured":"Jing Y, Yang J, Johnson DB, Moslehi JJ, Han L. Harnessing big data to characterize immune-related adverse events. Nat Rev Clin Oncol. 2022;19(4):269\u201380. https:\/\/doi.org\/10.1038\/s41571-021-00597-8.","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"1202_CR26","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/j.jaip.2020.09.021","volume":"9","author":"RJ Yu","year":"2021","unstructured":"Yu RJ, Krantz MS, Phillips EJ, Stone CA Jr. Emerging causes of drug-induced anaphylaxis: a review of anaphylaxis-associated reports in the FDA adverse event reporting system (FAERS). J Allergy Clin Immunol Pract. 2021;9(2):819-29.e2. https:\/\/doi.org\/10.1016\/j.jaip.2020.09.021.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"2","key":"1202_CR27","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/j.numecd.2021.10.003","volume":"32","author":"Z Yang","year":"2022","unstructured":"Yang Z, Yu M, Mei M, Chen C, Lv Y, Xiang L, et al. The association between GLP-1 receptor agonist and diabetic ketoacidosis in the FDA adverse event reporting system. Nutr Metab Cardiovasc Dis. 2022;32(2):504\u201310. https:\/\/doi.org\/10.1016\/j.numecd.2021.10.003.","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"9","key":"1202_CR28","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.1007\/s00125-013-2957-2","volume":"56","author":"JH Ellenbroek","year":"2013","unstructured":"Ellenbroek JH, T\u00f6ns HA, van Westerouen Meeteren MJ, de Graaf N, Hanegraaf MA, Rabelink TJ, et al. Glucagon-like peptide-1 receptor agonist treatment reduces beta cell mass in normoglycaemic mice. Diabetologia. 2013;56(9):1980\u20136. https:\/\/doi.org\/10.1007\/s00125-013-2957-2.","journal-title":"Diabetologia"},{"issue":"7","key":"1202_CR29","doi-asserted-by":"publisher","first-page":"2118","DOI":"10.2337\/dc12-2713","volume":"36","author":"PC Butler","year":"2013","unstructured":"Butler PC, Elashoff M, Elashoff R, Gale EA. A critical analysis of the clinical use of incretin-based therapies: Are the GLP-1 therapies safe? Diabetes Care. 2013;36(7):2118\u201325. https:\/\/doi.org\/10.2337\/dc12-2713.","journal-title":"Diabetes Care"},{"issue":"7","key":"1202_CR30","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1001\/jamainternmed.2013.2720","volume":"173","author":"S Singh","year":"2013","unstructured":"Singh S, Chang HY, Richards TM, Weiner JP, Clark JM, Segal JB. Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study. JAMA Intern Med. 2013;173(7):534\u20139. https:\/\/doi.org\/10.1001\/jamainternmed.2013.2720.","journal-title":"JAMA Intern Med"},{"issue":"2","key":"1202_CR31","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.diabres.2015.02.013","volume":"108","author":"D Soranna","year":"2015","unstructured":"Soranna D, Bosetti C, Casula M, Tragni E, Catapano AL, Vecchia CL, et al. Incretin-based drugs and risk of acute pancreatitis: a nested-case control study within a healthcare database. Diabetes Res Clin Pract. 2015;108(2):243\u20139. https:\/\/doi.org\/10.1016\/j.diabres.2015.02.013.","journal-title":"Diabetes Res Clin Pract"},{"key":"1202_CR32","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.g2780","volume":"348","author":"JL Faillie","year":"2014","unstructured":"Faillie JL, Azoulay L, Patenaude V, Hillaire-Buys D, Suissa S. Incretin based drugs and risk of acute pancreatitis in patients with type 2 diabetes: cohort study. BMJ. 2014;348: g2780. https:\/\/doi.org\/10.1136\/bmj.g2780.","journal-title":"BMJ"},{"issue":"9","key":"1202_CR33","doi-asserted-by":"publisher","first-page":"6188","DOI":"10.1039\/c7sc02189e","volume":"8","author":"J Shi","year":"2017","unstructured":"Shi J, Deng Q, Wan C, Zheng M, Huang F, Tang B. Fluorometric probing of the lipase level as acute pancreatitis biomarkers based on interfacially controlled aggregation-induced emission (AIE). Chem Sci. 2017;8(9):6188\u201395. https:\/\/doi.org\/10.1039\/c7sc02189e.","journal-title":"Chem Sci"},{"issue":"6","key":"1202_CR34","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1111\/dom.12885","volume":"19","author":"H Storgaard","year":"2017","unstructured":"Storgaard H, Cold F, Gluud LL, Vilsb\u00f8ll T, Knop FK. Glucagon-like peptide-1 receptor agonists and risk of acute pancreatitis in patients with type 2 diabetes. Diabetes Obes Metab. 2017;19(6):906\u20138. https:\/\/doi.org\/10.1111\/dom.12885.","journal-title":"Diabetes Obes Metab"},{"issue":"7","key":"1202_CR35","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/s41575-021-00457-x","volume":"18","author":"AP Klein","year":"2021","unstructured":"Klein AP. Pancreatic cancer epidemiology: understanding the role of lifestyle and inherited risk factors. Nat Rev Gastroenterol Hepatol. 2021;18(7):493\u2013502. https:\/\/doi.org\/10.1038\/s41575-021-00457-x.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"11","key":"1202_CR36","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1038\/s41395-018-0255-9","volume":"113","author":"O Sadr-Azodi","year":"2018","unstructured":"Sadr-Azodi O, Oskarsson V, Discacciati A, Videhult P, Askling J, Ekbom A. Pancreatic cancer following acute pancreatitis: a population-based matched cohort study. Am J Gastroenterol. 2018;113(11):1711\u20139. https:\/\/doi.org\/10.1038\/s41395-018-0255-9.","journal-title":"Am J Gastroenterol"},{"key":"1202_CR37","unstructured":"The Medicines and Healthcare products Regulatory Agency (MHRA). MHRA warns about GLP-1 receptor agonists: reports of diabetic ketoacidosis when concomitant insulin was rapidly reduced or discontinued. 2019. Available at: https:\/\/www.gov.uk\/drug-safety-update\/glp-1-receptor-agonists-reports-of-diabeticketoacidosis-when-concomitant-insulin-was-rapidly-reduced-ordiscontinued. Accessed 22 Dec 2020."},{"key":"1202_CR38","unstructured":"US FDA. FDA is evaluating the need for regulatory action about DKA associated with GLP-1RA. Available at: https:\/\/www.fda.gov\/drugs\/questions-and-answers-fdas-adverse-event-reporting-system-faers\/october-december-2019-potential-signals-serious-risksnew-safety-information-identified-fda-adverse. Accessed 22 Dec 2021."},{"issue":"2","key":"1202_CR39","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.jhep.2021.02.034","volume":"75","author":"SA Harrison","year":"2021","unstructured":"Harrison SA, Gawrieh S, Roberts K, Lisanti CJ, Schwope RB, Cebe KM, et al. Prospective evaluation of the prevalence of non-alcoholic fatty liver disease and steatohepatitis in a large middle-aged US cohort. J Hepatol. 2021;75(2):284\u201391. https:\/\/doi.org\/10.1016\/j.jhep.2021.02.034.","journal-title":"J Hepatol"},{"issue":"3","key":"1202_CR40","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1530\/JOE-19-0007","volume":"241","author":"S Kalavalapalli","year":"2019","unstructured":"Kalavalapalli S, Bril F, Guingab J, Vergara A, Garrett TJ, Sunny NE, et al. Impact of exenatide on mitochondrial lipid metabolism in mice with nonalcoholic steatohepatitis. J Endocrinol. 2019;241(3):293\u2013305. https:\/\/doi.org\/10.1530\/JOE-19-0007.","journal-title":"J Endocrinol"},{"issue":"5","key":"1202_CR41","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1111\/jgh.15787","volume":"37","author":"WK Chan","year":"2022","unstructured":"Chan WK, Tan SS, Chan SP, Lee YY, Tee HP, Mahadeva S, et al. Malaysian Society of Gastroenterology and Hepatology consensus statement on metabolic dysfunction-associated fatty liver disease. J Gastroenterol Hepatol. 2022;37(5):795\u2013811. https:\/\/doi.org\/10.1111\/jgh.15787.","journal-title":"J Gastroenterol Hepatol"},{"issue":"6","key":"1202_CR42","doi-asserted-by":"publisher","first-page":"2318","DOI":"10.1002\/hep.30670","volume":"69","author":"K Cusi","year":"2019","unstructured":"Cusi K. Incretin-based therapies for the management of nonalcoholic fatty liver disease in patients with type 2 diabetes. Hepatology. 2019;69(6):2318\u201322. https:\/\/doi.org\/10.1002\/hep.30670.","journal-title":"Hepatology"},{"key":"1202_CR43","unstructured":"US FDA. FDA is evaluating the need for regulatory action about drug-induced liver injury associated with GLP-1RA. Available at: https:\/\/www.fda.gov\/drugs\/questions-and-answers-fdas-adverse-event-reporting-system-faers\/january-march-2021-potential-signals-serious-risksnew-safety-information-identified-fda-adverse. Accessed 1 Jan 2022."},{"issue":"12","key":"1202_CR44","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","volume":"384","author":"PN Newsome","year":"2021","unstructured":"Newsome PN, Buchholtz K, Cusi K, Linder M, Okanoue T, Ratziu V, et al. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N Engl J Med. 2021;384(12):1113\u201324. https:\/\/doi.org\/10.1056\/NEJMoa2028395.","journal-title":"N Engl J Med"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-022-01202-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-022-01202-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-022-01202-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,29]],"date-time":"2022-10-29T08:06:31Z","timestamp":1667030791000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-022-01202-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,30]]},"references-count":44,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["1202"],"URL":"https:\/\/doi.org\/10.1007\/s40261-022-01202-1","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,30]]},"assertion":[{"value":"12 September 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No funding was received to conduct this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Tingxi Wu and Yang Zhang designed the research, analyzed the data, and wrote a draft of the manuscript. Yanfeng Shi, Shangyi Liu, Kefu Yu and Mei Zhao contributed to the data collection and analysis. Yang Zhang and Zhigang Zhao directed the research and revised the manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"Tingxi Wu, Yang Zhang, Yanfeng Shi, Kefu Yu, Mei Zhao, Shangyi Liu, and Zhigang Zhao have no conflicts of interest to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"The data are available in the FAERS ().","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"No institutional ethics approval was required because this study utilized anonymized data from an open-access database.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publication"}},{"value":"Not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}